drugset / Trial / NCT02207010
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
Phase 0
Completed
20 enrolled
St. Joseph's Hospital and Medical Center, Phoenix
American Society of Clinical Oncology · collabBarbara Ann Karmanos Cancer Institute · collabThe Ben & Catherine Ivy Foundation · collabTranslational Genomics Research Institute · collab
NaSingle-groupOpen-labelOther
Summary
This study would test how much of the new drug, AZD1775, is present in tumor, blood, and skin after one dose of the drug. The purpose of the study is not to treat the tumor, but to see if the drug actually gets into the tumor cells. This study does not replace routine cancer treatment.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-12-31
- Completion
- 2019-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | 100 mg | Oral |
| Subject | Adavosertib | Small molecule | 200 mg | Oral |
| Subject | Adavosertib | Small molecule | 400 mg | Oral |